Anlocon: Amlodipine Besylate Tablets Obtained Drug Registration Certificate.

Anglicon announcement, the company has obtained the Drug Registration Certificate for Amlodipine Besylate Tablets issued by the National Medical Products Administration. This drug is used for the treatment of hypertension and symptomatic treatment of coronary heart disease. The company received the notification of acceptance for drug marketing authorization application in December 2023 and was recently approved. According to relevant national policies, obtaining the Drug Registration Certificate this time is equivalent to passing a consistency evaluation, which will further enrich the company's product pipeline.